Table 5.
Outlier cases with pathological review, IHC and mutation profile.
| ID | 841 | 1120 | 220 | 895 | 511 | 1034 | 611 |
|---|---|---|---|---|---|---|---|
| Original Subtype | Serous carcinoma | Serous carcinoma | Serous carcinoma | Low-grade endometrioid carcinoma | Low-grade endometrioid carcinoma | Low-grade endometrioid carcinoma | Low-grade endometrioid carcinoma |
| Review | mixed serous (80%) and low-grade endometrioid carcinoma, with adjacent endometrium showing focal complex atypical hyperplasia | mixed serous (60%) and low-grade endometrioid carcinoma, with adjacent endometrium showing complex atypical hyperplasia | Grade 3 endometrioid with clear cell changes | Grade 2 endometrioid (extensively myometrial-invasive and LVI) | Grade 3 endometrioid | Mixed low-grade (G2) endometrioid and serous carcinoma | Serous carcinoma |
| p53-IHCa | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| ER-IHCb | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| P16-IHCb | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| PR-IHCb | 0 | 1 | 0 | 1 | 1 | 1 | NA |
| PTEN-IHCc | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| ARID1A | p.Q420*, p.R1335* | p.Q2176fs | p.Q548fs, p.G1847fs | ||||
| PTEN | p.L265fs | splice site acceptor | |||||
| PIK3CA | p.G106V, p.V344M | p.Q546K, p.H1047Y | Y1021C | ||||
| KRAS | p.G13D | p.G12A | |||||
| PPP2R1A | p.R182W | p.P179L | |||||
| TP53 | p.R282W | p.H193L | p.R248Q | p.S241F | |||
| CTNNB1 | |||||||
| BRAF | p.A526V, p.P403fs | ||||||
| PPP2R5C |
a
Scoring; 0= loss of expression, 1= normal expression, 2= over-expression
b
Scoring; 0= no expression, 1= over-expression
c
Scoring; 1=normal expression, 0= loss of expression